1 on 1 Demo – Device42

Device42 Discovery & Inventory insights enables you to solve problems faster and manage IT more efficiently

Source: www.device42.com

Categories: General HCPs, General Medicine News

Tags: demo,Device42,ITOps

Tweets with this article

If you're unable to find a convenient slot for @Device42 regular weekly demo why not schedule dedicated 1:1 time with one of their product experts? They'll personally guide you through their product and address any queries you have. https://t.co/cvlNiKm61n #demo #Device42 #ITOps

Amusement Park Rides Appear Safe for People With Cardiac Devices | Docwire News

Researchers assessed the safety of rides for patients with cardiac implantable electronic devices in an effort to see if they result in electromagnetic interference.

DocWire News November 18, 2024

Evaluating the Strengths of AI in Practice

How can physicians explore and embrace AI technology?

NEJM Catalyst November 18, 2024

Misuse of Race in the Interpretation of HbA1c | Annals of Internal Medicine

Hemoglobin A1c (HbA1c) is a test for diabetes used to monitor glycemic control. Racial differences in the absolute levels of HbA1c have been observed. Some…

Annals of Int Med November 18, 2024

Home

AI Agents to Run Your Factory

Evan Kirstel the $B2B Techfluencer November 18, 2024

New ACIP recommendations: COVID vaccine frequency for seniors and RSV vaccine safety concerns

The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about new ACIP recommendations for COVID,…

AMA November 18, 2024

Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial

Objectives To assess the efficacy and safety of the non-hormonal, neurokinin 3 receptor antagonist, fezolinetant, to treat moderate-severe vasomotor symptoms associated with menopause in individuals…

The BMJ November 18, 2024

Related Articles